Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

740

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab
DRUG: Placebo (for Dupilumab)
OTHER: Topical Corticosteroid (TCS)

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]